Research summary ·
Vitiligo onset following anti-inflammatory biological therapy: a scoping review.
Written based on 1 research study on PubMed, searched on 13 Nov 2026.
What was studied
This review looked at vitiligo that began after biologic drugs. Vitiligo is a skin disease where patches lose their color. The drugs here block signals that drive inflammation. The team gathered and summed up past published articles. They used 18 articles that told of 39 people in total.
What they found
The mean age of the people was 43 years, and more were men. Most cases came after drugs that block TNF alpha. These include infliximab, adalimumab and certolizumab pegol. Others followed ixekizumab, secukinumab, ustekinumab or dupilumab. Vitiligo began a median of 5 months after the drug started. The range was 1.5 to 24 months. Some cases involved the face and neck. Some people stopped or changed their drug. Some cases stayed stable, some got color back, and a few got worse.
What it means for patients
The authors say vitiligo is reported as a possible side effect of these drugs. Still, they say proof that the drugs cause it is weak. Cases with drugs other than TNF blockers seem to be only isolated reports. The authors note these people also had other autoimmune diseases. They think this points to chance, not cause.
Why it is not certain yet
The review covers only 39 people from 18 articles. The authors say proof that the drugs cause vitiligo is still weak. They say more research is needed to understand the link. A review can only be as good as the studies in it.
Source
Vitiligo onset following anti-inflammatory biological therapy: a scoping review.
PubMed · PMID 42903092We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Vitiligo publications